bioAffinity Technologies wins Japan patent allowance for CyPath Lung AI algorithm
BIAF•bioAffinity Technologies received a notice of allowance from Japan’s patent office for an AI-driven method supporting its CyPath Lung cancer-risk prediction test; the company expects the patent to issue after paying the required fee.
1. Patent allowance
The allowance covers early-stage lung cancer detection in sputum using automated flow cytometry with machine learning. bioAffinity Technologies expects the Japanese patent to be issued following payment of the required fee.
2. Patent portfolio
The company’s portfolio includes 22 granted patents worldwide and 36 pending applications.
